The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non–small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials

The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non–small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials

Introduction: Aidi injection (Aidi) is composed of cantharidin, astragaloside, ginsenoside, and elentheroside E. As an important adjuvant therapy, Aidi in combination with gemcitabine and cisplatin (GP) is often used in the treatment of non-small cell lung cancer (NSCLC).Objectives: We performed a n...

Full description

Bibliographic Details
Main Authors: Cheng-Qiong Wang, Xiao-Tian Zheng, Xiao-Fan Chen, Hong Jiang, Jun Huang, Yuan Jiang, Shan-Shan Hu, Xiao-Rong Huang, Shi-Yu Liu, Qi-Hai Gong, Ji-Hong Feng, Xue Xiao, Xiao-Fei Li, Zheng Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Pharmacology
Subjects:
aidi injection
non-small cell lung cancer
gemcitabine and cisplatin
randomized controlled trial
optimal adjuvant strategy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.582447/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.582447/full

Similar Items